Latest filings (excl ownership)
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
20 Mar 24
EFFECT
Notice of effectiveness
11 Dec 23
424B3
Prospectus supplement
8 Dec 23
CORRESP
Correspondence with SEC
7 Dec 23
UPLOAD
Letter from SEC
7 Dec 23
S-3
Shelf registration
6 Dec 23
8-K
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results
13 Nov 23
8-K
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
27 Sep 23
8-K
Termination of a Material Definitive Agreement
6 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
23 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K/A
Departure of Directors or Certain Officers
28 Apr 23
8-K
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
24 Apr 23
8-K
Departure of Directors or Certain Officers
11 Apr 23
8-K
UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
27 Mar 23
8-K
Other Events
17 Mar 23
424B5
Prospectus supplement for primary offering
17 Mar 23
S-8
Registration of securities for employees
15 Mar 23
10-K
2022 FY
Annual report
15 Mar 23
8-K
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
UNITY Biotechnology, Inc. Reports Third Quarter 2022
8 Nov 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
1 Nov 22
424B5
Prospectus supplement for primary offering
25 Oct 22
EFFECT
Notice of effectiveness
25 Oct 22
CORRESP
Correspondence with SEC
20 Oct 22
UPLOAD
Letter from SEC
20 Oct 22
8-K
Material Modifications to Rights of Security Holders
19 Oct 22
S-3
Shelf registration
14 Oct 22
DEF 14A
Definitive proxy
13 Sep 22
PRE 14A
Preliminary proxy
30 Aug 22
8-K
UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering
22 Aug 22
Latest ownership filings
4
Alexander Hieu Nguyen
27 Mar 24
SC 13G/A
Alyeska Investment Group, L.P.
14 Feb 24
4
Anirvan Ghosh
5 Feb 24
4
Anirvan Ghosh
31 Jan 24
4
Anirvan Ghosh
3 Nov 23
4
Anirvan Ghosh
31 Oct 23
4
Anirvan Ghosh
15 Sep 23
144
Notice of proposed sale of securities
15 Sep 23
4
Anirvan Ghosh
3 Aug 23
144
Notice of proposed sale of securities
3 Aug 23
4
Anirvan Ghosh
1 Aug 23
144
Notice of proposed sale of securities
1 Aug 23
4
Anirvan Ghosh
27 Jun 23
144
Notice of proposed sale of securities
27 Jun 23
4
Camille D Samuels
26 Jun 23
4
PAUL L BERNS
26 Jun 23
4
Gilmore Neil O'Neill
26 Jun 23
4
Margo R Roberts
26 Jun 23
4
Michael P. Samar
26 Jun 23
4
Keith R Leonard
26 Jun 23
4
Nathaniel E David
26 Jun 23
4
Anirvan Ghosh
15 Jun 23
144
Notice of proposed sale of securities
14 Jun 23
4
Lynne Marie Sullivan
12 May 23
4
Alexander Hieu Nguyen
12 May 23
4
Anirvan Ghosh
12 May 23
SC 13G/A
FMR LLC
10 May 23
4
Anirvan Ghosh
3 May 23
144
Notice of proposed sale of securities
3 May 23
4
Anirvan Ghosh
2 May 23
144
Notice of proposed sale of securities
2 May 23
4
Anirvan Ghosh
3 Apr 23
4
Jamie Dananberg
3 Apr 23
4
Jamie Dananberg
15 Mar 23
4
Anirvan Ghosh
15 Mar 23
SC 13G
Alyeska Investment Group, L.P.
14 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
4
Jamie Dananberg
3 Feb 23
4
Anirvan Ghosh
3 Feb 23
4
Anirvan Ghosh
31 Jan 23